iBio plans first — in — human trial of obesity drug candidate IBIO — 610 in H1 2027
iBio highlighted preclinical data on IBIO-610 from an obese non-human primate study, with results already presented at EASD on Oct. 1, 2026. In combination with semaglutide, IBIO-610 shifted weight loss toward fat, suggesting improved muscle preservation versus semaglutide alone. iBio expects to start first-in-human tr